Neurocrine Biosciences reports 44% sales growth in Q1 2026 and plans to acquire Soleno Therapeutics.

Neurocrine Biosciences announced a 44% year-over-year increase in net product sales to $811 million in Q1 2026, driven by strong demand for INGREZZA and CRENESSITY. The company reaffirmed its full-year 2026 sales guidance for INGREZZA at $2.7 to $2.8 billion. It also entered a definitive agreement to acquire Soleno Therapeutics for $2.9 billion, adding VYKAT XR for treating hyperphagia in Prader-Willi syndrome, expected to close in Q2 2026. Neurocrine is advancing its pipeline with new clinical trials in schizophrenia and obesity, positioning itself for sustained growth and innovation in neuropsychiatric and endocrine disorders.